IMVAMUNE

BIOLOGICAL6 trials

Sponsors

Bavarian Nordic, Ivan Litvinov

Conditions

Atopic DermatitisBasal Cell CarcinomaHIV InfectionHIV InfectionsNon-melanoma Skin CancerSmallpoxSquamous Cell Carcinoma

Phase 1

Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

CompletedNCT00390078

Bavarian NordicHIV Infections

Start: 2007-01-31End: 2009-01-31Target: 30Updated: 2009-07-10

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer

TerminatedNCT04410874

Ivan LitvinovBasal Cell Carcinoma, Non-melanoma Skin Cancer, Squamous Cell Carcinoma

Start: 2020-11-16End: 2023-05-23Updated: 2024-03-07

Phase 2

An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

CompletedNCT00189930

Bavarian NordicHIV Infection

Start: 2005-04-30End: 2006-12-31Updated: 2012-10-01

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

CompletedNCT00316602

Bavarian NordicAtopic Dermatitis

Start: 2006-07-31End: 2010-04-30Updated: 2019-01-09

An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees

CompletedNCT00686582

Bavarian NordicSmallpox

Start: 2008-08-31End: 2009-06-30Updated: 2019-03-13

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

CompletedNCT00857493

Bavarian NordicSmallpox

Start: 2009-06-30End: 2010-08-31Updated: 2019-01-10

Related Papers

LB1579. A single and a two-dose regimen of MVA-BN elicit similar memory responses to a boost vaccination two years after the initial regimen, indicating potential flexibility for a delayed second dose of MVA-BN in the ongoing monkeypox emergency

Open Forum Infectious Diseases2022-12-011 citations

One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines

The Journal of Infectious Diseases2022-11-2150 citations

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects

PLoS ONE2016-06-2180 citations

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis

PLoS ONE2015-10-06113 citations